Dietary interventions in multiple sclerosis: Development and pilot-testing of an evidence based patient education program

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Riemann Lorenz, Karin ^a,c   Eilers, Marlene ^a   Von Geldern, Gloria ^b   Schulz, Karl Heinz ^a   Köpke, Sascha ^c   Heesen, Christoph ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTENT ANALYSIS; CONTROLLED STUDY; DIET THERAPY; DIETARY COMPLIANCE; EDUCATION PROGRAM; EVIDENCE BASED PRACTICE; FEMALE; HEALTH CARE NEED; HEALTH SURVEY; HUMAN; INFORMATION SEEKING; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDITERRANEAN DIET; MULTIPLE SCLEROSIS; PATIENT EDUCATION; PATIENT SATISFACTION; PILOT STUDY; PROGRAM DEVELOPMENT; PROGRAM FEASIBILITY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT; CASE CONTROL STUDY; INTERNET; LIFESTYLE; MIDDLE AGED; PROGRAM EVALUATION; PSYCHOLOGY; QUESTIONNAIRE;

ADULT; CASE-CONTROL STUDIES; DIET, MEDITERRANEAN; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; INTERNET; LIFE STYLE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PILOT PROJECTS; PROGRAM EVALUATION; SURVEYS AND QUESTIONNAIRES;

EID: 84992223500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0165246     Document Type: Article

References (46)

1. Belbasis L, Bellou V, Evangelou E, Ioannidis JPA, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. The Lancet Neurology. 2015; 14(3):263-73. doi: 10.1016/s1474-4422(14)70267-4 PMID: 25662901
2. Evans C, Beland S-G, Kulaga S, Wolfson C, Kingwell E, Marriott J, et al. Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review. Neuroepidemiology. 2013; 40(3):195-210. doi: 10.1159/000342779 PMID: 23363936
3. Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nature reviews Neurology. 2014; 10(4):225-38. doi: 10.1038/nrneurol.2014.37 PMID: 24638138.
4. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, et al. International Multiple Sclerosis Genetics Consortium. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature genetics. 2013; 45(11):1353-60. doi: 10.1038/ng.2770 PMID: 24076602
5. Waubant E, Cross A. MS and related disorders: groundbreaking news. The Lancet Neurology. 2014; 13(1):11-3. doi: 10.1016/S1474-4422(13)70284-9 PMID: 24331785
6. Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G. Dietary interventions for multiple sclerosis. Cochrane Database of Systematic Reviews. 2012. 12:CD004192. doi: 10.1002/14651858. CD004192.pub3 PMID: 23235605
7. Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature. 2013; 496(7446):518-22. doi: 10.1038/nature11868 PMID: 23467095
8. Storoni M, Plant GT. The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple Sclerosis. Mult Scler Int. 2015; 2015. doi: 10.1155/2015/681289 PMID: 26839705
9. Wekerle H. Nature plus nurture: the triggering of multiple sclerosis. Swiss medical weekly. 2015; 145: w14189. doi: 10.4414/smw.2015.14189 PMID: 26430854.
10. Jagannath VA, Fedorowicz Z, Asokan GV, Robak EW, Whamond L. Vitamin D for the management of multiple sclerosis. Database: Cochrane Database of Systematic Reviews. 2010. 12:CD008422. doi: 10.1002/14651858.CD008422.pub2 PMID: 21154396
11. Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, van der Meer DM. The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis. Nutritional neuroscience. 2015; 18(3):125-36. doi: 10.1179/1476830514Y.0000000117 PMID: 24628020
12. Schwarz S, Knorr C, Geiger H, Flachenecker P. Complementary and alternative medicine for multiple sclerosis. Multiple Sclerosis. 2008; 14(8):1113-9. doi: 10.1177/1352458508092808 PMID: 18632773
13. Leong EM, Semple SJ, Angley M, Siebert W, Petkov J, McKinnon RA. Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia and why? Complementary therapies in medicine. 2009; 17(4):216-23. doi: 10.1016/j.ctim.2009.03.001 PMID: 19632549.
14. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.cochranehandbook. org
15. Hedstrom AK, Akerstedt T, Hillert J, Olsson T, Alfredsson L. Shift work at young age is associated with increased risk for multiple sclerosis. Annals of neurology. 2011; 70(5):733-41. doi: 10.1002/ana.22597 PMID: 22006815
16. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Canadian journal of applied sport sciences Journal canadien des sciences appliquees au sport. 1985; 10(3):141-6. PMID: 4053261
17. Godin G, Shepard RJ. Godin Leisure Time Exercise Questionnaire Medicine and Science in Sports & Exercise. 1997; 29(6):36-8.
18. Mohr DC, Hart SL, Julian L, Tasch ES. Screening for depression among patients with multiple sclerosis: two questions may be enough. Multiple Sclerosis. 2007; 13(2):215-9. doi: 10.1177/1352458506070926 PMID: 17439887
19. Schwarzer R, Jerusalem, M. Skalen zur Erfassung von Lehrer-und Schülermerkmalen. Dokumentation der psychometrischen Verfahren im Rahmen der Wissenschaftlichen Begleitung des Modellversuchs Selbstwirksame Schulen [Internet]. Berlin; 1999. Available from: http://www.psyc.de/skalendoku.pdf
20. Bunge M, Mühlhauser I, Steckelberg A. What constitutes evidence-based patient information? Overview of discussed criteria. Patient education and counseling. 2010; 78(3):316-28. doi: 10.1016/j.pec. 2009.10.029 PMID: 20005067.
21. Deutsches Netzwerk Evidenzbasierte Medizin. Gute Praxis Gesundheitsinformation. Berlin: 2015. Available from: http://www.ebm-netzwerk.de/gpgi
22. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008; 337(sep29 1: ):a1655-a. doi: 10.1136/bmj.a1655 PMID: 18824488
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLOS Med. 2009; 6(7): e1000097. doi: 10.1371/journal. pmed1000097 PMID: 19621072
24. Bates D. Trial of polyunsaturated fatty acids in non-relapsing multiple sclerosis. British Medical Journal. 1977; 2(6092)):932-33.
25. Bates D, Fawcett PR, Shaw DA, Weightman D. Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis. BMJ. 1978; 2(6149):1390-1. PMID: 363236
26. Bates D, Cartlidge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989; 52(1):18-22. PMID: 2540285
27. Harbige LS, Sharief MK. Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. The British journal of nutrition. 2007; 98 Suppl 1(S1: ):S46-53. doi: 10.1017/S0007114507833010 PMID: 17922959
28. Millar JHD, Zilkha KJ, Langman MJS, Wright HP, Smith AD, Belin J, et al. Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. BMJ. 1973; 1(5856):765-8. PMID: 4571680
29. Pantzaris MC, Loukaides GN, Ntzani EE, Patrikios IS. A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial. BMJ open. 2013; 3(4). doi: 10.1136/bmjopen-2012-002170 PMID: 23599375
30. Paty DW. Double-blind trial of linoleic acid in multiple sclerosis. Archives of neurology. 1983; 40 (11):693-4. PMID: 6354153
31. Torkildsen Ø, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, et al. ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study): A Randomized, Double-Blind, Placebo-Controlled Trial. Archives of Neurology. 2012; 69(8). doi: 10.1001/archneurol.2012.283 PMID: 22507886
32. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al. Low fat dietary intervention with ω-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2005; 73(5):397-404. doi: 10.1016/j.plefa.2005.05.024 PMID: 16099630
33. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010; 74(23):1852-9. doi: 10.1212/WNL. 0b013e3181e1cec2 PMID: 20427749
34. Derakhshandi H, Etemadifar M, Feizi A, Abtahi SH, Minagar A, Abtahi MA, et al. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Acta neurologica Belgica. 2013; 113 (3):257-63. doi: 10.1007/s13760-012-0166-2 PMID: 23250818.
35. Golan D, Halhal B, Glass-Marmor L, Staun-Ram E, Rozenberg O, Lavi I, et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC neurology. 2013; 13(1):60. doi: 10.1186/1471-2377-13-60 PMID: 23767916
36. Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis Journal. 2012; 18 (8):1144-51. doi: 10.1177/1352458511434607 PMID: 22354743
37. Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. Effects of Adjunct Low-Dose Vitamin D on Relapsing-Remitting Multiple Sclerosis Progression: Preliminary Findings of a Randomized Placebo-Controlled Trial. Multiple Sclerosis International. 2012; 2012:1-7. doi: 10.1155/2012/452541 PMID: 22567287
38. Soilu-Hanninen M, Aivo J, Lindstrom BM, Elovaara I, Sumelahti ML, Farkkila M, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012; 83(5):565-71. doi: 10.1136/jnnp-2011-301876 PMID: 22362918
39. Swank RL, Brewer-Dugan B. Effect of low saturated fat diet in early and late cases of multiple sclerosis. The Lancet. 1990; 336:37-9.
40. Overcomingms.org [Internet]. Australia: Overcoming Multiple Sclerosis. Available from: https://overcomingms.org/.
41. Adam O. Ernährungsrichtlinien bei Multipler Sklerose. 1st ed. Mü nster: Deutscher Medizin Verlag; 2007.
42. Evers J. Die Evers-Diät: Chancen bei MS, Diabetes und anderen Stoffwechsel-Erkrankungen. 13th ed. Stuttgart, Germany: Haug; 2002.
43. Kluge-Therapie.de [Internet]. Berlin: GSGN e.V.; Available from: http://www.kluge-therapie.de.
44. Fratzer U. Hoffmann, H. Schach der MS. Bestandsaufnahme und neue Strategie gegen Multiple-Sklerose. Ein Report fü r Betroffene. 2nd ed. Geretsried b. München printul Verlagsgesellschaft mbH; 1990.
45. Max Rubner-Institut-Bundesforschungsinstitut fü r Ernährung und Lebensmittel. Nationale Verzehrsstudie II-Ergebnisbericht Teil 2. Karlsruhe; 2008. Available from https://www.mri.bund.de/fileadmin/MRI/Institute/EV/NVSII-Abschlussbericht-Teil-2.pdf
46. Möhler R, Köpke S, Meyer G. Criteria for Reporting the Development and Evaluation of Complex Interventions in healthcare: revised guideline (CReDECI 2). Trials. 2015; 16:204. doi: 10.1186/s13063-015-0709-y PMID: 25935741